Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection

Bibliography

• Dunn W, Chou C, Li H, et al. Functional profiling of a human cytomegalovirus genome. Proc Natl Acade Sci USA 2003;100(24):14223-8
   PubMed Web of Science ®Google Scholar
• Mocarski ESJ, Shenk T, Pass RF. Cytomegaloviruses. In: Knipe DM, Howley PM, editors. Fields virology. 5th edition. Lippincott, Williams & Wilkins; Philadelphia: 2007. p. 2701:2772
   Google Scholar
• Kalejta RF. Tegument proteins of human cytomegalovirus. Microbiol Mol Biol Rev 2008;72(2):249-65. table of contents
   PubMed Web of Science ®Google Scholar
• Isomura H, Stinski MF, Murata T, et al. The human cytomegalovirus gene products essential for late viral gene expression assemble into prereplication complexes before viral DNA replication. J Virol 2011;85(13):6629-44
   PubMed Web of Science ®Google Scholar
• Sinclair J, Sissons P. Latency and reactivation of human cytomegalovirus. J Gen Virol 2006;87(Pt 7):1763-79
   PubMedGoogle Scholar
• Rafailidis PI, Mourtzoukou EG, Varbobitis IC, Falagas ME. Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review. Virol J 2008;5:47
   PubMed Web of Science ®Google Scholar
• Razonable RR, Emery VC. Management of CMV infection and disease in transplant patients. 27-29 February 2004. Herpes 2004;11(3):77-86
   PubMedGoogle Scholar
• Pass RF. Cytomegalovirus. In: Long SS, Pickering LK, Prober CG, editors. Principles and practice of pediatric infectious diseases. 4th edition. Elsevier Saunders; New York, NY: 2012
   Google Scholar
• Sacher T, Andrassy J, Kalnins A, et al. Shedding light on the elusive role of endothelial cells in cytomegalovirus dissemination. PLoS Pathog 2011;7(11):e1002366
   PubMedGoogle Scholar
• Zanghellini F, Boppana SB, Emery VC, et al. Asymptomatic primary cytomegalovirus infection: virologic and immunologic features. J Infect Dis 1999;180(3):702-7
   PubMed Web of Science ®Google Scholar
• Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009;9(Suppl 4):S78-86
   PubMed Web of Science ®Google Scholar
• Klenerman P, Hill A. T cells and viral persistence: lessons from diverse infections. Nat Immunol 2005;6(9):873-9
   PubMed Web of Science ®Google Scholar
• Snydman DR, Werner BG, Heinze-Lacey B, et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 1987;317(17):1049-54
   PubMed Web of Science ®Google Scholar
• Plotkin SA, Starr SE, Friedman HM, et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Ann Intern Med 1991;114(7):525-31
   PubMed Web of Science ®Google Scholar
• Falagas ME, Snydman DR, Ruthazer R, et al. Primary cytomegalovirus infection in liver transplant recipients: comparison of infections transmitted via donor organs and via transfusions. Boston Center for Liver Transplantation CMVIG Study Group. Clinical Infectious Dis 1996;23(2):292-7
   PubMed Web of Science ®Google Scholar
• Kumar D, Chernenko S, Moussa G, et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009;9(5):1214-22
   PubMed Web of Science ®Google Scholar
• Manuel O, Husain S, Kumar D, et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis 2013;56(6):817-24
   PubMed Web of Science ®Google Scholar
• Heiden D, Ford N, Wilson D, et al. Cytomegalovirus retinitis: the neglected disease of the AIDS pandemic. PLoS Med 2007;4(12):e334
   PubMed Web of Science ®Google Scholar
• Rosenthal LS, Fowler KB, Boppana SB, et al. Cytomegalovirus shedding and delayed sensorineural hearing loss: results from longitudinal follow-up of children with congenital infection. Pediatr Infect Dis J 2009;28(6):515-20
   PubMed Web of Science ®Google Scholar
• Noyola DE, Demmler GJ, Williamson WD, et al. Cytomegalovirus urinary excretion and long term outcome in children with congenital cytomegalovirus infection. Congenital CMV Longitudinal Study Group. Pediatr Infect Dis J 2000;19(6):505-10
   PubMed Web of Science ®Google Scholar
• Pass RF, Stagno S, Britt WJ, Alford CA. Specific cell-mediated immunity and the natural history of congenital infection with cytomegalovirus. J Infect Dis 1983;148(6):953-61
   PubMed Web of Science ®Google Scholar
• Staras SA, Dollard SC, Radford KW, et al. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis 2006;43(9):1143-51
   PubMed Web of Science ®Google Scholar
• Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004. Clin Infect Dis 2010;50(11):1439-47
   PubMed Web of Science ®Google Scholar
• Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 2010;20(4):202-13
   PubMed Web of Science ®Google Scholar
• Stagno S, Reynolds DW, Pass RF, Alford CA. Breast milk and the risk of cytomegalovirus infection. N Engl J Med 1980;302(19):1073-6
   PubMed Web of Science ®Google Scholar
• Klemola E, Von Essen R, Henle G, Henle W. Infectious-mononucleosis-like disease with negative heterophil agglutination test. Clinical features in relation to Epstein-Barr virus and cytomegalovirus antibodies. J Infect Dis 1970;121(6):608-14
   PubMed Web of Science ®Google Scholar
• Pannuti CS, Vilas Boas LS, Angelo MJ, et al. Cytomegalovirus mononucleosis in children and adults: differences in clinical presentation. Scand J Infect Dis 1985;17(2):153-6
   PubMed Web of Science ®Google Scholar
• Horwitz CA, Henle W, Henle G, et al. Clinical and laboratory evaluation of cytomegalovirus-induced mononucleosis in previously healthy individuals. Report of 82 cases. Medicine 1986;65(2):124-34
   PubMed Web of Science ®Google Scholar
• Eddleston M, Peacock S, Juniper M, Warrell DA. Severe cytomegalovirus infection in immunocompetent patients. Clin Infect Dis 1997;24(1):52-6
   PubMed Web of Science ®Google Scholar
• Laing RB, Dykhuizen RS, Smith CC, Molyneaux PJ. Parenteral ganciclovir treatment of acute CMV infection in the immunocompetent host. Infection 1997;25(1):44-6
   PubMed Web of Science ®Google Scholar
• Fowler KB, Stagno S, Pass RF. Maternal age and congenital cytomegalovirus infection: screening of two diverse newborn populations, 1980-1990. J Infect Dis 1993;168(3):552-6
   PubMed Web of Science ®Google Scholar
• Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol 2007;17(5):355-63
   PubMed Web of Science ®Google Scholar
• Boppana SB, Pass RF, Britt WJ, et al. Symptomatic congenital cytomegalovirus infection: neonatal morbidity and mortality. Pediatr Infect Dis J 1992;11(2):93-9
   PubMed Web of Science ®Google Scholar
• Istas AS, Demmler GJ, Dobbins JG, Stewart JA. Surveillance for congenital cytomegalovirus disease: a report from the National Congenital Cytomegalovirus Disease Registry. Clin Infect Dis 1995;20(3):665-70
   PubMed Web of Science ®Google Scholar
• Smith RJ, Bale JFJr, White KR. Sensorineural hearing loss in children. Lancet 2005;365(9462):879-90
   PubMed Web of Science ®Google Scholar
• Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010;89(7):779-95
   PubMed Web of Science ®Google Scholar
• de Jong MD, Galasso GJ, Gazzard B, et al. Summary of the II international symposium on cytomegalovirus. Antivir Res 1998;39(3):141-62
   PubMed Web of Science ®Google Scholar
• The TH, van den Berg AP, van Son WJ, et al. Monitoring for cytomegalovirus after organ transplantation: a clinical perspective. Transplant Proc 1993;25(5 Suppl 4):5-9
   PubMed Web of Science ®Google Scholar
• Kusne S, Shapiro R, Fung J. Prevention and treatment of cytomegalovirus infection in organ transplant recipients. Transplant Infect Dis 1999;1(3):187-203
   PubMedGoogle Scholar
• Rubin RH, Cosimi AB, Tolkoff-Rubin NE, et al. Infectious disease syndromes attributable to cytomegalovirus and their significance among renal transplant recipients. Transplantation 1977;24(6):458-64
   PubMed Web of Science ®Google Scholar
• Kotton CN. Management of cytomegalovirus infection in solid organ transplantation. Nat Rev Nephrol 2010;6(12):711-21
   PubMed Web of Science ®Google Scholar
• Hardy AM, Wajszczuk CP, Suffredini AF, et al. Pneumocystis carinii pneumonia in renal-transplant recipients treated with cyclosporine and steroids. J Infect Dis 1984;149(2):143-7
   PubMed Web of Science ®Google Scholar
• Husni RN, Gordon SM, Longworth DL, et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis 1998;26(3):753-5
   PubMed Web of Science ®Google Scholar
• Asano-Mori Y, Kanda Y, Oshima K, et al. Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplantation. Int J Hematol 2008;87(3):310-18
   PubMed Web of Science ®Google Scholar
• Ljungman P. Cytomegalovirus infections in transplant patients. Scand J Infect Dis Suppl 1996;100:59-63
   PubMedGoogle Scholar
• Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003;101(2):407-14
   PubMed Web of Science ®Google Scholar
• Mofenson LM, Brady MT, Danner SP, et al. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep 2009;58(RR-11):1-166
   PubMedGoogle Scholar
• Guibert G, Warszawski J, Le Chenadec J, et al. Decreased risk of congenital cytomegalovirus infection in children born to HIV-1-infected mothers in the era of highly active antiretroviral therapy. Clinical Infect Dis 2009;48(11):1516-25
   PubMed Web of Science ®Google Scholar
• Ashton WT, Karkas JD, Field AK, Tolman RL. Activation by thymidine kinase and potent antiherpetic activity of 2’-nor-2’-deoxyguanosine (2’NDG). Biochem Biophys Res Commun 1982;108(4):1716-21
   PubMed Web of Science ®Google Scholar
• Martin JC, Dvorak CA, Smee DF, et al. 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine: a new potent and selective antiherpes agent. J Med Chem 1983;26(5):759-61
   PubMed Web of Science ®Google Scholar
• Cheng YC, Huang ES, Lin JC, et al. Unique spectrum of activity of 9-[(1,3-dihydroxy-2-propoxy)methyl]-guanine against herpesviruses in vitro and its mode of action against herpes simplex virus type 1. Proc Natl Acad Sci USA 1983;80(9):2767-70
   PubMed Web of Science ®Google Scholar
• Field AK, Davies ME, DeWitt C, et al. 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication. Proc Natl Acad Sci USA 1983;80(13):4139-43
   PubMed Web of Science ®Google Scholar
• Smith KO, Galloway KS, Kennell WL, et al. A new nucleoside analog, 9-[[2-hydroxy-1-(hydroxymethyl)ethoxyl]methyl]guanine, highly active in vitro against herpes simplex virus types 1 and 2. Antimicrob Agents Chemother 1982;22(1):55-61
   PubMed Web of Science ®Google Scholar
• Jenson HB, Leach CT, Montalvo EA, et al. Absence of herpesvirus in AIDS-associated smooth-muscle tumors. N Engl J Med 1996;335(22):1690
   PubMed Web of Science ®Google Scholar
• Crumpacker CS. Ganciclovir. N Engl J Med 1996;335(10):721-9
   PubMed Web of Science ®Google Scholar
• Jacobson MA, de Miranda P, Cederberg DM, et al. Human pharmacokinetics and tolerance of oral ganciclovir. Antimicrob Agents Chemother 1987;31(8):1251-4
   PubMed Web of Science ®Google Scholar
• Cytovene-IV [package insert]. Genentech USA, Inc; San Francisco, CA: 2010
   Google Scholar
• Cheng YC, Grill SP, Dutschman GE, et al. Metabolism of 9-(1,3-dihydroxy-2-propoxymethyl)guanine, a new anti-herpes virus compound, in herpes simplex virus-infected cells. J Biol Chem 1983;258(20):12460-4
   PubMed Web of Science ®Google Scholar
• Freitas VR, Smee DF, Chernow M, et al. Activity of 9-(1,3-dihydroxy-2-propoxymethyl)guanine compared with that of acyclovir against human, monkey, and rodent cytomegaloviruses. Antimicrob Agents Chemother 1985;28(2):240-5
   PubMed Web of Science ®Google Scholar
• Sullivan V, Talarico CL, Stanat SC, et al. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 1992;358(6382):162-4
   PubMed Web of Science ®Google Scholar
• Littler E, Stuart AD, Chee MS. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 1992;358(6382):160-2
   PubMed Web of Science ®Google Scholar
• Chee MS, Lawrence GL, Barrell BG. Alpha-, beta- and gammaherpesviruses encode a putative phosphotransferase. J Gen Virol 1989;70(Pt 5):1151-60
   PubMed Web of Science ®Google Scholar
• Erice A. Resistance of human cytomegalovirus to antiviral drugs. Clin Microbiol Rev 1999;12(2):286-97
   PubMed Web of Science ®Google Scholar
• Lurain NS, Thompson KD, Holmes EW, Read GS. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents. J Virol 1992;66(12):7146-52
   PubMed Web of Science ®Google Scholar
• Michaels MG, Greenberg DP, Sabo DL, Wald ER. Treatment of children with congenital cytomegalovirus infection with ganciclovir. Pediatr Infect Dis J 2003;22(6):504-9
   PubMed Web of Science ®Google Scholar
• Markham A, Faulds D. Ganciclovir. An update of its therapeutic use in cytomegalovirus infection. Drugs 1994;48(3):455-84
   PubMed Web of Science ®Google Scholar
• Kimberlin DW, Lin CY, Sanchez PJ, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr 2003;143(1):16-25
   PubMed Web of Science ®Google Scholar
• Whitley RJ, Cloud G, Gruber W, et al. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis 1997;175(5):1080-6
   PubMed Web of Science ®Google Scholar
• Nigro G, Scholz H, Bartmann U. Ganciclovir therapy for symptomatic congenital cytomegalovirus infection in infants: a two-regimen experience. J Pediatr 1994;124(2):318-22
   PubMed Web of Science ®Google Scholar
• Kimberlin DW. Antiviral therapy for cytomegalovirus infections in pediatric patients. Semin Pediatr Infect Dis 2002;13(1):22-30
   PubMedGoogle Scholar
• Cocohoba JM, McNicholl IR. Valganciclovir: an advance in cytomegalovirus therapeutics. Ann Pharmacother 2002;36(6):1075-9
   PubMed Web of Science ®Google Scholar
• Valcyte [package insert]. Genentech USA, Inc; San Francisco, CA: 2013
   Google Scholar
• Meine Jansen CF, Toet MC, Rademaker CM, et al. Treatment of symptomatic congenital cytomegalovirus infection with valganciclovir. J Perinat Med 2005;33(4):364-6
   PubMed Web of Science ®Google Scholar
• Muller A, Eis-Hubinger AM, Brandhorst G, et al. Oral valganciclovir for symptomatic congenital cytomegalovirus infection in an extremely low birth weight infant. J Perinatol 2008;28(1):74-6
   PubMed Web of Science ®Google Scholar
• Schulzke S, Buhrer C. Valganciclovir for treatment of congenital cytomegalovirus infection. Eur J Pediatr 2006;165(8):575-6
   PubMed Web of Science ®Google Scholar
• Demmler GJ. Infectious Diseases Society of America and Centers for Disease Control. Summary of a workshop on surveillance for congenital cytomegalovirus disease. Rev Infect Dis 1991;13(2):315-29
   PubMedGoogle Scholar
• Whitley RJ. The use of antiviral drugs during the neonatal period. Clin Perinatol 2012;39(1):69-81
   PubMed Web of Science ®Google Scholar
• Trang JM, Kidd L, Gruber W, et al. Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group. Clin Pharmacol Ther 1993;53(1):15-21
   PubMed Web of Science ®Google Scholar
• Whitley RJ, Cloud G, Gruber W, et al. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis 1997;175(5):1080-6
   PubMed Web of Science ®Google Scholar
• Zhou XJ, Gruber W, Demmler G, et al. Population pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group. Antimicrob Agents Chemother 1996;40(9):2202-5
   PubMed Web of Science ®Google Scholar
• Nigro G, Scholz H, Bartmann U. Ganciclovir therapy for symptomatic congenital cytomegalovirus infection in infants: a two-regimen experience. J Pediatr 1994;124(2):318-22
   PubMed Web of Science ®Google Scholar
• Galli L, Novelli A, Chiappini E, et al. Valganciclovir for congenital CMV infection: a pilot study on plasma concentration in newborns and infants. Pediatr Infect Dis J 2007;26(5):451-3
   PubMed Web of Science ®Google Scholar
• Lombardi G, Garofoli F, Villani P, et al. Oral valganciclovir treatment in newborns with symptomatic congenital cytomegalovirus infection. Eur J Clin Microbiol Infect Dis 2009;28(12):1465-70
   PubMed Web of Science ®Google Scholar
• Acosta EP, Brundage RC, King JR, et al. Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. Clin Pharmacol Ther 2007;81(6):867-72
   PubMed Web of Science ®Google Scholar
• Kimberlin DW, Acosta EP, Sanchez PJ, et al. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis 2008;197(6):836-45
   PubMed Web of Science ®Google Scholar
• Kimberlin DW, Lin CY, Sanchez PJ, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr 2003;143(1):16-25
   PubMed Web of Science ®Google Scholar
• Oliver SE, Cloud GA, Sanchez PJ, et al. Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system. J Clin Virol 2009;46(Suppl 4):S22-6
   PubMed Web of Science ®Google Scholar
• Kimberlin DW JP, Sanchez PJ, Ahmed A, et al. and the NIAID Collaborative Antiviral Study Group (CASG). Six months versus six weeks of oral valganciclovir for infants with symptomatic congenital cytomegalovirus (CMV) disease with and without central nervous system (CNS) involvement: Results of a Phase III, randomized, double-blind, placebo-controlled, multinational study (Oral Abstract #LB-1). IDWeek; San Francisco, CA: 2013
   Google Scholar
• Rayes N, Oettle H, Schmidt CA, et al. Preemptive therapy in CMV-antigen positive patients after liver transplantation–a prospective trial. Ann Transplant 1999;4(2):12-17
   PubMedGoogle Scholar
• Kelly J, Hurley D, Raghu G. Comparison of the efficacy and cost effectiveness of pre-emptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients. J Heart Lung Transplant 2000;19(4):355-9
   PubMed Web of Science ®Google Scholar
• Egan JJ, Lomax J, Barber L, et al. Preemptive treatment for the prevention of cytomegalovirus disease: in lung and heart transplant recipients. Transplantation 1998;65(5):747-52
   PubMed Web of Science ®Google Scholar
• Mori T, Okamoto S, Matsuoka S, et al. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 2000;25(7):765-9
   PubMed Web of Science ®Google Scholar
• Reddy V, Hao Y, Lipton J, et al. Management of allogeneic bone marrow transplant recipients at risk for cytomegalovirus disease using a surveillance bronchoscopy and prolonged pre-emptive ganciclovir therapy. J Clin Virol 1999;13(3):149-59
   PubMed Web of Science ®Google Scholar
• Moretti S, Zikos P, Van Lint MT, et al. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study. Bone Marrow Transplant 1998;22(2):175-80
   PubMed Web of Science ®Google Scholar
• Rubin RH, Tolkoff-Rubin NE. Antimicrobial strategies in the care of organ transplant recipients. Antimicrob Agents Chemother 1993;37(4):619-24
   PubMed Web of Science ®Google Scholar
• Duncan SR, Paradis IL, Dauber JH, et al. Ganciclovir prophylaxis for cytomegalovirus infections in pulmonary allograft recipients. Am Rev Respir Dis 1992;146(5 Pt 1):1213-15
   PubMed Web of Science ®Google Scholar
• Merigan TC, Renlund DG, Keay S, et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992;326(18):1182-6
   PubMed Web of Science ®Google Scholar
• Green M, Kaufmann M, Wilson J, Reyes J. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children. Clin Infect Dis 1997;25(6):1344-9
   PubMed Web of Science ®Google Scholar
• Seu P, Winston DJ, Holt CD, et al. Long-term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with CMV-seropositive donors. Transplantation 1997;64(11):1614-17
   PubMed Web of Science ®Google Scholar
• Filler G, Lampe D, von Bredow MA, et al. Prophylactic oral ganciclovir after renal transplantation-dosing and pharmacokinetics. Pediatr Nephrol 1998;12(1):6-9
   PubMed Web of Science ®Google Scholar
• Danziger-Isakov LA, DelaMorena M, Hayashi RJ, et al. Cytomegalovirus viremia associated with death or retransplantation in pediatric lung-transplant recipients. Transplantation 2003;75(9):1538-43
   PubMed Web of Science ®Google Scholar
• Spivey JF, Singleton D, Sweet S, et al. Safety and efficacy of prolonged cytomegalovirus prophylaxis with intravenous ganciclovir in pediatric and young adult lung transplant recipients. Pediatr Transplant 2007;11(3):312-18
   PubMed Web of Science ®Google Scholar
• Kalil AC, Florescu DF. Why valganciclovir should not be indicated for liver recipients and high-dose acyclovir should not be removed from international cytomegalovirus guidelines. Transplantation 2011;91(1):e8-9. author reply e10
   PubMed Web of Science ®Google Scholar
• Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004;4(4):611-20
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Valcyte (valganciclovir HCL tablets). Dear Healthcare Professional Letter. 2003. Available from: http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm169502.htm [ Accessed 7 November 2014]
   Google Scholar
• Bedel AN, Hemmelgarn TS, Kohli R. Retrospective review of the incidence of cytomegalovirus infection and disease after liver transplantation in pediatric patients: comparison of prophylactic oral ganciclovir and oral valganciclovir. Liver Transpl 2012;18(3):347-54
   PubMed Web of Science ®Google Scholar
• Levitsky J, Singh N, Wagener MM, et al. A survey of CMV prevention strategies after liver transplantation. Am J Transplant 2008;8(1):158-61
   PubMed Web of Science ®Google Scholar
• Villeneuve D, Brothers A, Harvey E, et al. Valganciclovir dosing using area under the curve calculations in pediatric solid organ transplant recipients. Pediatr Transplant 2013;17(1):80-5
   PubMed Web of Science ®Google Scholar
• Zhao W, Fakhoury M, Fila M, et al. Individualization of valganciclovir prophylaxis for cytomegalovirus infection in pediatric kidney transplant patients. Ther Drug Monit 2012;34(3):326-30
   PubMed Web of Science ®Google Scholar
• Madan RP, Campbell AL, Shust GF, et al. A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients. Transplantation 2009;87(9):1318-24
   PubMed Web of Science ®Google Scholar
• Martin M, Goyette N, Ives J, Boivin G. Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis. J Clin Virol 2010;47(4):321-4
   PubMed Web of Science ®Google Scholar
• Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 2004;4(12):725-38
   PubMed Web of Science ®Google Scholar
• Launay E, Theoret Y, Litalien C, et al. Pharmacokinetic profile of valganciclovir in pediatric transplant recipients. Pediatr Infect Dis J 2012;31(4):405-7
   PubMed Web of Science ®Google Scholar
• Tolman RL, Field AK, Karkas JD, et al. 2’-Nor-cGMP: a seco-cyclic nucleotide with powerful anti-DNA-viral activity. Biochem Biophys Res Commun 1985;128(3):1329-35
   PubMed Web of Science ®Google Scholar
• Biron KK, Stanat SC, Sorrell JB, et al. Metabolic activation of the nucleoside analog 9-[(2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc Natl Acad Sci USA 1985;82(8):2473-7
   PubMed Web of Science ®Google Scholar
• Perrottet N, Decosterd LA, Meylan P, et al. Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. Clin Pharmacokinet 2009;48(6):399-418
   PubMed Web of Science ®Google Scholar
• Fishman JA, Doran MT, Volpicelli SA, et al. Dosing of intravenous ganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplant recipients. Transplantation 2000;69(3):389-94
   PubMed Web of Science ®Google Scholar
• Wiltshire H, Paya CV, Pescovitz MD, et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 2005;79(11):1477-83
   PubMed Web of Science ®Google Scholar
• Åsberg A, Bjerre A, Neely M. New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients. Pediatr Transplant 2014;18(1):103-11
   PubMed Web of Science ®Google Scholar
• Vezina HE, Brundage RC, Balfour HHJr. Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients. Br J Clin Pharmacol 2014;78(2):343-52
   PubMed Web of Science ®Google Scholar
• Caldes A, Colom H, Armendariz Y, et al. Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus. Antimicrob Agents Chemother 2009;53(11):4816-24
   PubMed Web of Science ®Google Scholar
• Perrottet N, Csajka C, Pascual M, et al. Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir. Antimicrob Agents Chemother 2009;53(7):3017-23
   PubMed Web of Science ®Google Scholar
• Vethamuthu J, Feber J, Chretien A, et al. Unexpectedly high inter- and intrapatient variability of ganciclovir levels in children. Pediatr Transplant 2007;11(3):301-5
   PubMed Web of Science ®Google Scholar
• Pescovitz MD, Ettenger RB, Strife CF, et al. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients. Transplant Infect Dis 2010;12(3):195-203
   PubMed Web of Science ®Google Scholar
• Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987;317(17):1098
   PubMed Web of Science ®Google Scholar
• Schwartz GJ, Feld LG, Langford DJ. A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatr 1984;104(6):849-54
   PubMed Web of Science ®Google Scholar
• Villeneuve D, Brothers A, Harvey E, et al. Valganciclovir dosing using area under the curve calculations in pediatric solid organ transplant recipients. Pediatr Transplant 2013;17(1):80-5
   PubMed Web of Science ®Google Scholar
• Posadas Salas MA, Taber DJ, Chua E, et al. Critical analysis of valganciclovir dosing and renal function on the development of cytomegalovirus infection in kidney transplantation. Transplant Infect Dis 2013;15(6):551-8
   PubMed Web of Science ®Google Scholar
• Trevillyan J, Angus P, Shelton E, et al. Electronic estimations of renal function are inaccurate in solid-organ transplant recipients and can result in significant underdosing of prophylactic valganciclovir. Antimicrob Agents Chemother 2013;57(8):4058-60
   PubMed Web of Science ®Google Scholar
• Czock D, Scholle C, Rasche FM, et al. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. Clin Pharmacol Ther 2002;72(2):142-50
   PubMed Web of Science ®Google Scholar
• Perrottet N, Robatel C, Meylan P, et al. Disposition of valganciclovir during continuous renal replacement therapy in two lung transplant recipients. J Antimicrob Chemother 2008;61(6):1332-5
   PubMed Web of Science ®Google Scholar
• Boulieu R, Bastien O, Bleyzac N. Pharmacokinetics of ganciclovir in heart transplant patients undergoing continuous venovenous hemodialysis. Ther Drug Monit 1993;15(2):105-7
   PubMed Web of Science ®Google Scholar
• Bastien O, Boulieu R, Bleyzac N, Estanove S. Clinical use of ganciclovir during renal failure and continuous hemodialysis. Intensive Care Med 1994;20(1):47-8
   PubMed Web of Science ®Google Scholar
• Gando S, Kameue T, Nanzaki S, et al. Pharmacokinetics and clearance of ganciclovir during continuous hemodiafiltration. Crit Care Med 1998;26(1):184-7
   PubMed Web of Science ®Google Scholar
• Horvatits T, Kitzberger R, Drolz A, et al. Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients. Antimicrob Agents Chemother 2014;58(1):94-101
   PubMed Web of Science ®Google Scholar
• McGloughlin S, Roberts JA, O’Donoghue S, et al. Ganciclovir pharmacokinetics and suggested dosing in continuous venovenous haemodiafiltration. Int J Antimicrob Agents 2011;37(1):90-2
   PubMed Web of Science ®Google Scholar
• Zhang B, Fila M, Fakhoury M, et al. Pharmacokinetics and dosage individualization of ganciclovir and valganciclovir in an infant with nephrotic syndrome associated with cytomegalovirus infection. J Antimicrob Chemother 2014;69(4):1150-1
   PubMed Web of Science ®Google Scholar
• Kimberlin DW, Acosta EP, Sanchez PJ, et al. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis 2008;197(6):836-45
   PubMed Web of Science ®Google Scholar
• Trofe-Clark J, Lemonovich TL. Interactions between anti-infective agents and immunosuppressants in solid organ transplantation. Am J Transplant 2013;13(Suppl 4):318-26
   PubMedGoogle Scholar
• Cimoch PJ, Lavelle J, Pollard R, et al. Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects. J Acquir Immune Defic Syndr Human Retrovirol 1998;17(3):227-34
   PubMedGoogle Scholar
• Morris DJ. Adverse effects and drug interactions of clinical importance with antiviral drugs. Drug Saf 1994;10(4):281-91
   PubMed Web of Science ®Google Scholar
• Luck S, Lovering A, Griffiths P, Sharland M. Ganciclovir treatment in children: evidence of subtherapeutic levels. Int J Antimicrob Agents 2011;37(5):445-8
   PubMed Web of Science ®Google Scholar
• Balfour HHJr, Chace BA, Stapleton JT, et al. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989;320(21):1381-7
   PubMed Web of Science ®Google Scholar
• Merigan TC, Renlund DG, Keay S, et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992;326(18):1182-6
   PubMed Web of Science ®Google Scholar
• Schmidt GM, Horak DA, Niland JC, et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med 1991;324(15):1005-11
   PubMed Web of Science ®Google Scholar
• Siberry GK, Abzug MJ, Nachman S, et al. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. Pediatr Infect Dis J 2013;32(Suppl 2):i-KK4
   PubMedGoogle Scholar
• Acosta EP, Brundage RC, King JR, et al. Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. Clin Pharmacol Ther 2007;81(6):867-72
   PubMed Web of Science ®Google Scholar
• Perrottet N, Manuel O, Lamoth F, et al. Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients. BMC Infect Dis 2010;10:2
   PubMed Web of Science ®Google Scholar
• Gimenez E, Solano C, Azanza JR, et al. Monitoring of trough plasma ganciclovir levels and peripheral blood cytomegalovirus (CMV)-Specific CD8+ T cells to predict CMV DNAemia clearance in preemptively treated allogeneic stem cell transplant recipients. Antimicrob Agents Chemother 2014;58(9):5602-5
   PubMed Web of Science ®Google Scholar
• Lilleri D, Gerna G, Zelini P, et al. Monitoring of human cytomegalovirus and virus-specific T-cell response in young patients receiving allogeneic hematopoietic stem cell transplantation. PLoS One 2012;7(7):e41648
   PubMed Web of Science ®Google Scholar
• Manuel O, Asberg A, Pang X, et al. Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease. Clin Infect Dis 2009;49(8):1160-6
   PubMed Web of Science ®Google Scholar